medigraphic.com
ISSN 0326-3428 (Impreso)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Número 2

<< Anterior Siguiente >>

Rev Nefrol Dial Traspl 2020; 40 (2)


Neoplasias y trasplante renal

Taylor, MF

Idioma: Español
Referencias bibliográficas: 73
Paginas: 161-171
Archivo PDF: 381.25 Kb.


FRAGMENTO

INTRODUCCIÓN

El trasplante renal se ha consolidado como la terapia sustitutiva de elección para pacientes con insuficiencia renal crónica, con aumento de la sobrevida y mejoría de la calidad de vida. Estos pacientes presentan una elevada incidencia de procesos oncológicos respecto de la población general, cuya diferencia varía según la neoplasia considerada. Por otra parte, los procesos oncológicos tienden a ser más agresivos y manifestarse a edades más tempranas. El desarrollo de métodos de screening, el estudio de factores de riesgo, el ajuste de medicación inmunosupresora, la implementación de estudios complementarios sobre los efectos de la terapéutica oncológica sobre el implante son algunos de los puntos a considerar.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cheung CY, Lam MF, Chu KH, Chow KM, TsangKY, Yuen SK, et al. Malignancies after kidneytransplantation: Hong Kong renal registry. Am JTransplant. 2012;12(11):3039-46.

  2. Collett D, Mumford L, Banner NR, Neuberger J,Watson C. Comparison of the incidence of malignancyin recipients of different types of organ: a UK Registryaudit. Am J Transplant. 2010;10(8):1889-96.

  3. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL,Israni AK, Snyder JJ, et al. Spectrum of cancer riskamong US solid organ transplant recipients. JAMA.2011;306(17):1891-901.

  4. Krynitz B, Edgren G, Lindelöf B, BaecklundE, Brattström C, Wilczek H, et al. Risk of skincancer and other malignancies in kidney, liver,heart and lung transplant recipients 1970 to 2008,a Swedish population-based study. Int J Cancer.2013;132(6):1429-38.

  5. Kyllönen L, Salmela K, Pukkala E. Cancer incidencein a kidney-transplanted population. Transpl Int.2000;13(Suppl. 1):S394-8.

  6. Li WH, Chen YJ, Tseng WC, Lin MW, Chen TJ, ChuSY, et al. Malignancies after renal transplantation inTaiwan: a nationwide population-based study. NephrolDial Transplant. 2012;27(2):833-9.

  7. Piselli P, Serraino D, Segoloni GP, Sandrini S, PireddaGB, Scolari MP, et al. Risk of de novo cancers aftertransplantation: results from a cohort of 7217 kidneytransplant recipients, Italy 1997-2009. Eur J Cancer.2013;49(2):336-44.

  8. Stewart JH, Vajdic CM, van Leeuwen MT, Amin J,Webster AC, Chapman JR, et al. The pattern of excesscancer in dialysis and transplantation. Nephrol DialTransplant. 2009;24(10):3225-31.

  9. Tessari G, Naldi L, Boschiero L, Minetti E, SandriniS, Nacchia F, et al. Incidence of primary and secondcancers in renal transplant recipients: a multicentercohort study. Am J Transplant. 2013;13(1):214-21.

  10. Vajdic CM, McDonald SP, McCredie MR, vanLeeuwen MT, Stewart JH, Law M, et al. Cancerincidence before and after kidney transplantation.JAMA. 2006;296(23):2823-31.

  11. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA,Jiang Y, Mao Y. Cancer incidence among Canadiankidney transplant recipients. Am J Transplant.2007;7(4):941-8.

  12. Yanik EL, Clarke CA, Snyder JJ, Pfeiffer RM, EngelsEA. Variation in cancer incidence among patientswith ESRD during kidney function and nonfunctionintervals. J Am Soc Nephrol. 2016;27(5):1495-504.

  13. Asch WS, Bia MJ. Oncologic issues and kidneytransplantation: a review of frequency, mortality, andscreening. Adv Chronic Kidney Dis. 2014;21(1):106-13.

  14. Dantal J, Hourmant M, Cantarovich D, GiralM, Blancho G, Dreno B, et al. Effect of long-termimmunosuppression in kidney-graft recipients oncancer incidence: randomised comparison of twocyclosporin regimens. Lancet. 1998;351(9103):623-8.

  15. Hojo M, Morimoto T, Maluccio M, Asano T,Morimoto K, Lagman M, et al. Cyclosporine inducescancer progression by a cell-autonomous mechanism.Nature. 1999;397(6719):530-4.

  16. Caillard S, Dharnidharka V, Agodoa L, Bohen E,Abbott K. Posttransplant lymphoproliferative disordersafter renal transplantation in the United States in eraof modern immunosuppression. Transplantation.2005;80(9):1233-43.

  17. Cheung CY, Tang SCW. An update on cancer afterkidney transplantation. Nephrol Dial Transplant.2019;34(6):914-20.

  18. Wong G, Hayen A, Chapman JR, Webster AC, WangJJ, Mitchell P, et al. Association of CKD and cancer riskin older people. J Am Soc Nephrol. 2009;20(6):1341-50.

  19. Cheung CY, Ma MKM, Chak WL, Tang SCW.Cancer risk in patients with diabetic nephropathy: Aretrospective cohort study in Hong Kong. Medicine(Baltimore). 2017;96(38):e8077.

  20. Maisonneuve P, Agodoa L, Gellert R, Stewart JH,Buccianti G, Lowenfels AB, et al. Cancer in patientson dialysis for end-stage renal disease: an internationalcollaborative study. Lancet. 1999;354(9173):93-9.

  21. Au E, Wong G, Chapman JR. Cancer inkidney transplant recipients. Nat Rev Nephrol.2018;14(8):508-20.

  22. Farrugia D, Mahboob S, Cheshire J, Begaj I, KhoslaS, Ray D, et al. Malignancy-related mortality followingkidney transplantation is common. Kidney Int.2014;85(6):1395-403.

  23. Chen DS, Mellman I. Oncology meets immunology:the cancer-immunity cycle. Immunity. 2013;39(1):1-10.

  24. Webster AC, Craig JC, Simpson JM, Jones MP,Chapman JR. Identifying high risk groups andquantifying absolute risk of cancer after kidneytransplantation: a cohort study of 15,183 recipients. AmJ Transplant. 2007;7(9):2140-51.

  25. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C.Cancer after kidney transplantation in the UnitedStates. Am J Transplant. 2004;4(6):905-13.

  26. Myron Kauffman H, McBride MA, Cherikh WS,Spain PC, Marks WH, Roza AM. Transplant tumorregistry: donor related malignancies. Transplantation.2002;74(3):358-62.

  27. Desai R, Collett D, Watson CJ, Johnson P, EvansT, Neuberger J. Cancer transmission from organdonors-unavoidable but low risk. Transplantation.2012;94(12):1200-7.

  28. Xiao D, Craig JC, Chapman JR, Dominguez-Gil B,Tong A, Wong G. Donor cancer transmission in kidneytransplantation: a systematic review. Am J Transplant.2013;13(10):2645-52.

  29. Lentine KL, Kasiske BL, Levey AS, Adams PL, AlberúJ, Bakr MA, et al. KDIGO Clinical Practice Guidelineon the evaluation and care of living kidney donors.Transplantation. 2017;101(8S Suppl 1):S1-S109.

  30. Brook NR, Gibbons N, Johnson DW, Nicol DL.Outcomes of transplants from patients with small renaltumours, live unrelated donors and dialysis wait-listedpatients. Transpl Int. 2010;23(5):476-83.

  31. Watson CJ, Roberts R, Wright KA, Greenberg DC,Rous BA, Brown CH, et al. How safe is it to transplantorgans from deceased donors with primary intracranialmalignancy? An analysis of UK Registry data. Am JTransplant. 2010;10(6):1437-44.

  32. Chui AK, Herbertt K, Wang LS, Kyd G, HodgemanG, Verran DJ, et al. Risk of tumor transmission intransplantation from donors with primary braintumors: an Australian and New Zealand registryreport. Transplant Proc. 1999;31(1-2):1266-7.

  33. Acuna SA, Huang JW, Dossa F, Shah PS, Kim SJ,Baxter NN. Cancer recurrence after solid organtransplantation: A systematic review and meta-analysis.Transplant Rev (Orlando). 2017;31(4):240-8.

  34. Chapman JR, Sheil AG, Disney AP. Recurrence ofcancer after renal transplantation. Transplant Proc.2001;33(1-2):1830-1.

  35. Viecelli AK, Lim WH, Macaskill P, ChapmanJR, Craig JC, Clayton P, et al. Cancer-specific and170all-cause mortality in kidney transplant recipientswith and without previous cancer. Transplantation.2015;99(12):2586-92.

  36. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A.Clinical practice guidelines on wait-listing for kidneytransplantation: consistent and equitable?Transplantation. 2012;94(7):703-13.

  37. Campbell S, Pilmore H, Gracey D, Mulley W, RussellC, McTaggart S. KHA-CARI guideline: recipientassessment for transplantation. Nephrology (Carlton).2013;18(6):455-62.

  38. European Renal Best Practice TransplantationGuideline Development Group. ERBP Guideline onthe management and evaluation of the kidney donorand recipient. Nephrol Dial Transplant. 2013;28(Suppl.2):ii1-71.

  39. Kälble T, Lucan M, Nicita G, Sells R, BurgosRevilla FJ, Wiesel M, et al. EAU guidelines on renaltransplantation. Eur Urol. 2005;47(2):156-66.

  40. Kasiske BL, Cangro CB, Hariharan S, Hricik DE,Kerman RH, Roth D, et al. The evaluation of renaltransplantation candidates: clinical practice guidelines.Am J Transplant. 2001;1(Suppl. 2):3-95.

  41. Knoll G, Cockfield S, Blydt-Hansen T, Baran D,Kiberd B, Landsberg D, et al. Canadian Society ofTransplantation: consensus guidelines on eligibility forkidney transplantation. CMAJ. 2005;173(10):S1-25.

  42. Segall L, Nistor I, Pascual J, Mucsi I, Guirado L,Higgins R, et al. Criteria for and appropriateness ofrenal transplantation in elderly patients with end-stagerenal disease: a literature review and position statementon behalf of the European Renal Association-EuropeanDialysis and Transplant Association DescartesWorking Group and European Renal Best Practice.Transplantation. 2016;100(10):e55-65.

  43. Lin JS, Piper MA, Perdue LA, Rutter CM, WebberEM, O’Connor E, et al. Screening for colorectalcancer: updated evidence report and systematic reviewfor the US Preventive Services Task Force. JAMA.2016;315(23):2576-94.

  44. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M,Humphrey L. Effectiveness of breast cancer screening:systematic review and meta-analysis to update the 2009U.S. preventive services task force recommendation.Ann Intern Med. 2016;164(4):244-55.

  45. Cristina Villaamil Lepori E. Hidroarsenicismocrónico regional endémico en Argentina. Acta BioquímClín Latinoam. 2015;49(1):83-104.

  46. Wong G, Howard K, Craig JC, Chapman JR. Costeffectivenessof colorectal cancer screening in renaltransplant recipients. Transplantation. 2008;85(4):532-41.

  47. Wong G, Howard K, Webster A, Chapman JR, CraigJC. The health and economic impact of cervical cancerscreening and human papillomavirus vaccinationin kidney transplant recipients. Transplantation.2009;87(7):1078-91.

  48. Acuna SA, Huang JW, Scott AL, Micic S, DalyC, Brezden-Masley C, et al. Cancer screeningrecommendations for solid organ transplant recipients:a systematic review of clinical practice guidelines. Am JTransplant. 2017;17(1):103-14.

  49. Janus N, Launay-Vacher V, Byloos E, Machiels JP, DuckL, Kerger J, et al. Cancer and renal insufficiency resultsof the BIRMA study. Br J Cancer. 2010;103(12):1815-21.

  50. Canter D, Kutikov A, Sirohi M, Street R, Viterbo R,Chen DY, et al. Prevalence of baseline chronic kidneydisease in patients presenting with solid renal tumors.Urology. 2011;77(4):781-5.

  51. Nakamura Y, Tsuchiya K, Nitta K, Ando M. Prevalenceof anemia and chronic kidney disease in cancer patients:clinical significance for 1-year mortality. Nihon JinzoGakkai Shi. 2011;53(1):38-45.

  52. Reshef R, Vardhanabhuti S, Luskin MR, HeitjanDF, Hadjiliadis D, Goral S, et al. Reductionof immunosuppression as initial therapy forposttransplantation lymphoproliferative disorder.Am J Transplant. 2011;11(2):336-47.

  53. Hope CM, Krige AJ, Barratt A, Carroll RP. Reductionsin immunosuppression after haematological or solidorgan cancer diagnosis in kidney transplant recipients.Transpl Int. 2015;28(11):1332-5.

  54. Chapman JR, Webster AC, Wong G. Cancer in thetransplant recipient. Cold Spring Harb Perspect Med.2013;3(7):a015677.

  55. Nichols LA, Adang LA, Kedes DH. Rapamycin blocksproduction of KSHV/HHV8: insights into the antitumoractivity of an immunosuppressant drug. PLoSOne. 2011;6(1):e14535.

  56. Basu G, Mohapatra A, Manipadam MT, Mani SE,John GT. Leflunomide with low-dose everolimus fortreatment of Kaposi’s sarcoma in a renal allograftrecipient. Nephrol Dial Transplant. 2011;26(10):3412-5.

  57. Yaich S, Charfeddine K, Zaghdane S, El Aoud N,Jarraya F, Kharrat M, et al. Sirolimus for the treatmentof Kaposi sarcoma after renal transplantation: a seriesof 10 cases. Transplant Proc. 2012;44(9):2824-6.

  58. Cullis B, D’Souza R, McCullagh P, Harries S,Nicholls A, Lee R, et al. Sirolimus-induced remission ofposttransplantation lymphoproliferative disorder. Am JKidney Dis. 2006;47(5):e67-72.

  59. Boratyńska M, Watorek E, Smolska D, PatrzałekD, Klinger M. Anticancer effect of sirolimus inrenal allograft recipients with de novo malignancies.Transplant Proc. 2007;39(9):2736-9.

  60. Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH,Wu CK. Programmed cell death 1 (PD-1) inhibitorsin renal transplant patients with advanced cancer: adouble-edged sword? Int J Mol Sci. 2019;20(9):e2194.

  61. Rousseau B, Guillemin A, Duvoux C, Neuzillet C,Tlemsani C, Compagnon P, et al. Optimal oncologicmanagement and mTOR inhibitor introduction aresafe and improve survival in kidney and liver allograftrecipients with de novo carcinoma. Int J Cancer.2019;144(4):886-96.

  62. de Francisco ALM, Macía M, Alonso F, García P,Gutierrez E, Quintana LF, et al. Onco-Nefrología: cáncer,quimioterapia y riñón. Nefrología. 2019;39(5):455-562.

  63. Edeani A, Cohen EP. Chapter 10: RadiationNephropathy [Internet]. En: Online Curricula: Onco-Nephrology, Mark A. Perazella (ed.). American Societyof Nephrology: 2016. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter10.pdf (Consulta: 10/06/2019).

  64. Jhaveri KD, Rosner MH. Chimeric antigen receptor Tcell therapy and the kidney: what the nephrologist needsto know. Clin J Am Soc Nephrol. 2018;13(5):796-8.

  65. Kougias P, Sharath S, Barshes NR, Lowery B, GarciaA, Pak T, et al. Impact of cumulative intravascularcontrast exposure on renal function in patients withocclusive and aneurysmal vascular disease. J Vasc Surg.2014;59(6):1644-50.

  66. Hong SI, Ahn S, Lee YS, Kim WY, Lim KS, Lee JH,et al. Contrast-induced nephropathy in patients withactive cancer undergoing contrast-enhanced computedtomography. Support Care Cancer. 2016;24(3):1011-7.

  67. Kidney Disease Improving Global Outcomes Group.KDIGO Clinical Practice Guideline for Acute KidneyInjury. Kidney Int Suppl. 2012;2(1)1-138.

  68. Sharma A, Mucino MJ, Ronco C. Renal functionalreserve and renal recovery after acute kidney injury.Nephron Clin Pract. 2014;127(1-4):94-100.

  69. Estados Unidos. National Cancer Institute,Division of Cancer Control and Population Sciences.Surveillance, Epidemiology and End Results Program(SEER) [Internet]. Disponible en: https://seer.cancer.gov/ (Consulta: 10/06/2019).

  70. Australian and New Zealand Dialysis and TransplantRegistry (ANZDATA) [Internet]. Disponible en:http://www.anzdata.org.au/v1/index.html (Consulta:10/06/2019).

  71. Israel Penn International Transplant Tumor Registry(IPITTR) [Internet]. Disponible en: https://ipittr.uc.edu/ (Consulta: 10/06/2019).

  72. Italian National Transplant Centre. The vigilanceand suveillance chain for medical products of humanorigin. A notify guide, 2018 [Internet]. Disponible en:https://www.notifylibrary.org/content/13-vigilanceand-surveillance-chain-medical-products-humanorigin-notify-guide-0 (Consulta: 10/06/2019).

  73. Registro Argentino de Tumores en Trasplante[Internet]. Disponible en https://docs.google.com/forms/d/e/1FAIpQLSeRtr8gKqi-_VhiPLq0BPg5-bGFIjsvrRccUBmvdcBOtOv7yg/viewform (Consulta:10/06/2019).




2020     |     www.medigraphic.com